DMD and Duchenne muscular dystrophy: Biomarkers commonly employed in DMD trials, such as such as levels of muscle fiber dystrophin or reductions in markers of muscle fiber injury, are inadequate for evaluating interventions that enhance muscle regeneration, as these endpoints fail to capture improvements in regenerative capacity.